Two-Year Follow Up of the LATERAL Clinical Trial: A Focus on Adverse Events

Georg M Wieselthaler, Liviu Klein, Anson W Cheung, Matthew R Danter, Martin Strueber, Claudius Mahr, Nahush A Mokadam, Simon Maltais, Edwin C McGee Jr, Georg M Wieselthaler, Liviu Klein, Anson W Cheung, Matthew R Danter, Martin Strueber, Claudius Mahr, Nahush A Mokadam, Simon Maltais, Edwin C McGee Jr

Abstract

Background: The LATERAL trial validated the safety and efficacy of the thoracotomy approach for implantation of the HeartWare HVAD System, leading to Food and Drug Administration approval. We sought to analyze 24-month adverse event (AE) rates, including a temporal analysis of the risk profile, associated with the thoracotomy approach for the HVAD system.

Methods: AEs from the LATERAL trial were evaluated over 2 years postimplant. Data was obtained from the Interagency Registry for Mechanically Assisted Circulatory Support database for 144 enrolled United States and Canadian patients. Temporal AE profiles were expressed as events per patient year.

Results: During 162.5 patient years of support, there were 25 driveline infections (0.15 events per patient year), 50 gastrointestinal bleeds (0.31 events per patient year), and 21 strokes (0.13 events per patient year). Longitudinal AE analysis at follow-up intervals of <30 and 30 to 180 days, and 6 to 12 and 12 to 24 months revealed the highest AE rate at <30 days, with a decrease in total AEs within the first 6 months. After 6 months, most AE rates either stabilized or decreased through 2 years, including a 95% overall freedom from disabling stroke.

Conclusions: Two-year follow-up of the LATERAL trial revealed a favorable morbidity profile in patients supported with the HVAD system, as AE rates were more likely to occur in the first 30 days postimplant, and overall AE rates were significantly reduced after 6 months. Importantly, 2-year freedom from disabling stroke was 95%. These data further support the improving AE profile of patients on long-term HVAD support. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02268942.

Keywords: heart failure; morbidity; sternotomy; thoracotomy.

Figures

Figure.
Figure.
Freedom from disabling strokes. A stroke is disabling if modified Rankin Scale (mRS) was 4 or 5 at 24 wk poststroke, the patient died within 24 wk of the stroke (mRS=6), or the 24-week mRS was missing and the latest recorded mRS was 4 or 5. Patients are censored at the first occurrence of transplant, device exchange to a different device, explant, or death.

References

    1. Wieselthaler GM, O Driscoll G, Jansz P, Khaghani A, Strueber M; HVAD Clinical Investigators. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant. 2010;29:1218–1225. doi: 10.1016/j.healun.2010.05.016
    1. Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard Frazier O, Icenogle T, Najjar SS, Boyce SW, et al. ; HeartWare Bridge to Transplant ADVANCE Trial Investigators. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2013;32:675–683. doi: 10.1016/j.healun.2013.04.004
    1. Schmitto JD, Molitoris U, Haverich A, Strueber M. Implantation of a centrifugal pump as a left ventricular assist device through a novel, minimized approach: upper hemisternotomy combined with anterolateral thoracotomy. J Thorac Cardiovasc Surg. 2012;143:511–513. doi: 10.1016/j.jtcvs.2011.07.046
    1. Meyer AL, Hahn J, von Samson-Himmelstjerna P, Garbade J, Barten M, Mohr FW, Strüber M. Minimal-invasive LVAD implantation, is it safe or even better? J Heart Lung Transplant. 2013;32:S58
    1. Popov AF, Hosseini MT, Zych B, Simon AR, Bahrami T. HeartWare left ventricular assist device implantation through bilateral anterior thoracotomy. Ann Thorac Surg. 2012;93:674–676. doi: 10.1016/j.athoracsur.2011.09.055
    1. Cheung A, Lamarche Y, Kaan A, Munt B, Doyle A, Bashir J, Janz P. Off-pump implantation of the HeartWare HVAD left ventricular assist device through minimally invasive incisions. Ann Thorac Surg. 2011;91:1294–1296. doi: 10.1016/j.athoracsur.2010.08.031
    1. Sileshi B, O’Hara BK, Davis ME, Haglund NA, Meng X, Deegan R, Stulak JM, Kushwaha SS, Shaw A, Maltais S. Outcomes of patients implanted using a left thoracotomy technique for a miniaturized centrifugal continuous-flow pump. ASAIO J. 2016;62:539–544. doi: 10.1097/MAT.0000000000000407
    1. McGee E, Jr, Danter M, Strueber M, Mahr C, Mokadam NA, Wieselthaler G, Klein L, Lee S, Boeve T, Maltais S, et al. . Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: the LATERAL clinical trial. J Heart Lung Transplant. 2019;38:344–351. doi: 10.1016/j.healun.2019.02.002
    1. OPTN Thoracic Committee. Four-month monitoring of heart allocation proposal to modify the Heart Allocation System. 2019. . Accessed March 1, 2021
    1. Rao P, Smith R, Khalpey Z. Potential impact of the proposed revised UNOS thoracic organ allocation system. Semin Thorac Cardiovasc Surg. 2018;30:129–133. doi: 10.1053/j.semtcvs.2018.01.001
    1. Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, et al. ; HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191–3200. doi: 10.1161/CIRCULATIONAHA.111.058412
    1. Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, et al. . The society of thoracic surgeons INTERMACS database annual report: evolving indications, outcomes, and scientific partnerships. Ann Thorac Surg. 2019;107:341–353. doi: 10.1016/j.athoracsur.2018.11.011
    1. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, Naftel DC. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36:1080–1086. doi: 10.1016/j.healun.2017.07.005
    1. Han JJ, Acker MA, Atluri P. Left ventricular assist devices: synergistic model between technology and medicine. Circulation. 2018;138:2841–2851. doi: 10.1161/CIRCULATIONAHA.118.035566
    1. Maltais S, Aaronson KD, Teuteberg JJ, Slaughter MS, Najjar SS, Jeevanandam V, Pham DT, McGee EC, Jr, Leadley K, Kormos RL. Adverse event rates change favorably over time for patients bridged with the HeartWare left ventricular assist device. ASAIO J. 2017;63:745–751. doi: 10.1097/MAT.0000000000000585
    1. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, et al. . Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376:451–460. doi: 10.1056/NEJMoa1602954
    1. Samura T, Yoshioka D, Toda K, Sakaniwa R, Shimizu M, Miyagawa S, Yoshikawa Y, Hata H, Saito S, Sakata Y, et al. . Risk of stroke early after implantation of a left ventricular assist device. J Thorac Cardiovasc Surg. 2019;157:259–267.e1. doi: 10.1016/j.jtcvs.2018.06.031
    1. Cho SM, Moazami N, Katz S, Bhimraj A, Shrestha NK, Frontera JA. Stroke risk following infection in patients with continuous-flow left ventricular assist device. Neurocrit Care. 2019;31:72–80. doi: 10.1007/s12028-018-0662-1
    1. Frontera JA, Starling R, Cho SM, Nowacki AS, Uchino K, Hussain MS, Mountis M, Moazami N. Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. J Heart Lung Transplant. 2017;36:673–683. doi: 10.1016/j.healun.2016.12.010
    1. Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, Takeda K, Takayama H, Fried J, Naka Y, et al. . Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transplant. 2016;35:1003–1009. doi: 10.1016/j.healun.2016.03.014
    1. Mahr C, Thinh Pham D, Mokadam NA, Silvestry SC, Cowger J, Kiernan MS, D’alessandro DA, Coglianese EE, Faraz Masood M, Kormos RL, et al. . Interpreting neurologic outcomes in a changing trial design landscape: an analysis of HVAD using a hybrid intention to treat population. ASAIO J. 2019;65:293–296. doi: 10.1097/MAT.0000000000000931
    1. Schramm R, Morshuis M, Schoenbrodt M, Boergermann J, Hakim-Meibodi K, Hata M, Gummert JF. Current perspectives on mechanical circulatory support. Eur J Cardiothorac Surg. 2019;55(suppl 1):i31–i37. doi: 10.1093/ejcts/ezy444
    1. Qu Y, McGiffin D, Kure C, Ozcelik B, Fraser J, Thissen H, Peleg AY. Biofilm formation and migration on ventricular assist device drivelines. J Thorac Cardiovasc Surg. 2020;159:491–502.e2. doi: 10.1016/j.jtcvs.2019.02.088
    1. Shehab S, Allida SM, Davidson PM, Newton PJ, Robson D, Jansz PC, Hayward CS. Right ventricular failure post LVAD implantation corrected with biventricular support: an in vitro model. ASAIO J. 2017;63:41–47. doi: 10.1097/MAT.0000000000000455
    1. Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, Burkhoff D. Mechanical circulatory support devices for acute right ventricular failure. Circulation. 2017;136:314–326. doi: 10.1161/CIRCULATIONAHA.116.025290

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj